Praxis Precision Medicines (PRAX) Misses Q3 EPS by 76c

Praxis Precision Medicines (NASDAQ: PRAX) reported Q3 EPS of ($2.75), $0.76 worse than the analyst estimate of ($1.99). Revenue for the quarter came in at $302 thousand versus the consensus estimate of $328.56 thousand.

For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.

You May Also Be Interested In

• CoreWeave signs new compute contracts at $40M per megawatt pricing
• Allergan Aesthetics releases small skin study on GLP-1 medication users
• ZenaTech added to Canada's Defence Drone Initiative supplier pool